Opnurasib

Overview

Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor. Opnurasib shows antitumor activity.

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Ras | Products > Signaling Pathways > PERK

Product Information

• Catalog No.: HY-139612
• CAS No.: 2653994-08-0
• Molecular Formula: C29H28ClN7O
• Molecular Weight: 526.03
• Purity: 98.20%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (3.95 mM); Clear solution
• Availability: In-stock

Source

Original product source